Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually.
2024年5月8日,波士頓(GLOBE NEWSWIRE)- Cue生物製品公司(納斯達克:CUE)是一家臨床階段的生物醫藥公司,開發一種新型療法生物製品,選擇性調節特異性疾病T細胞,今天宣佈將於2024年5月13日至17日在波士頓和虛擬會議上舉行的第20屆PEGS波士頓峯會(必備的蛋白質和抗體工程峯會)上提供兩個海報展示。
Presentation Details
報告詳情
Date and Time: Monday, May 13 from 7:00 a.m. – 4:30 p.m. and Tuesday, May 14 from 9:00 a.m. – 12:00 p.m. EDT
Session: Poster Session A
Poster number: A028
Title: Immuno-STATs for Targeted Depletion of B Cells in Autoimmune Diseases
Presenter: Nitin Kumar, Scientist, Biologics Discovery and Innovation, Cue Biopharma
日期和時間:東部時間5月13日星期一早上7:00到下午4:30,星期二5月14日上午9:00到中午12:00
會議:海報展示會場A
海報編號:A028
標題:針對自身免疫性疾病的B細胞靶向清除的免疫STATs
演講者:Cue生物製品公司生物製品發現和創新科學家Nitin Kumar
Dr. Kumar will discuss Cue Biopharma's newly deployed CUE-500 series of bispecific Immuno-STAT biologics, designed to redirect and activate cytotoxic anti-viral memory T cells to deplete pathogenic B cells, which is a therapeutically relevant mechanism for the treatment of several autoimmune diseases.
Kumar博士將討論Cue生物製品公司新推出的CUE-500系列雙特異性免疫STAT生物製品,旨在重定向和激活細胞毒性抗病毒記憶T細胞,以清除病原性B細胞,這是治療幾種自身免疫性疾病的一種治療相關機制。
Date and Time: Tuesday, May 14 from 2:00 p.m. – 4:00 p.m. and Wednesday, May 15 from 9:00 a.m. – 7:30 p.m. EDT
Session: Poster Session B
Poster number: B023
Title: Immuno-STATs (ISTs): A Novel and Unique T-Cell Engager Platform for the Treatment of Immuno-Oncology and Autoimmune Diseases
Presenter: Ahmet Vakkasoglu, Associate Director, Biologics Discovery and Innovation, Cue Biopharma
日期和時間:東部時間5月14日星期二下午2:00到4:00,星期三5月15日上午9:00到下午7:30
會議:海報展示會場B
海報編號:B023
標題:免疫STAT(ISTs):治療免疫腫瘤學和自身免疫性疾病的新型獨特T細胞結合劑平台
演講者:Cue生物製品公司生物製品發現和創新的副總裁Ahmet Vakkasoglu
Dr. Vakkasoglu will present an overview of Cue Biopharma's Immuno-STAT platform and biologics. This will include a discussion of our lead oncology assets, which have demonstrated clinical anti-tumor activity, as well as an overview of our next generation platforms and molecules for the treatment of cancer, autoimmune and inflammatory diseases.
Vakkasoglu博士將介紹Cue生物製品公司的免疫STAT平台和生物製品,包括我們的抗腫瘤主要資產,已經展示了臨床抗腫瘤活性,以及我們下一代的平台和分子的概述,用於治療癌症、自身免疫性和炎症性疾病。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
關於cue biopharma
cue biopharma是一家臨床階段生物製品公司,正在開發一種新型的注射生物製品類別,以有選擇性地在患者體內直接接觸和調節疾病特異性T細胞。該公司的專有平台Immuno-STAT(選擇性靶向和改變T細胞)和生物製品旨在通過選擇性調節疾病特異性T細胞來利用體內免疫系統的治癒潛力,而不會產生廣泛的系統免疫調節不良反應。
總部位於馬薩諸塞州波士頓,我們由一支專業的管理團隊和獨立的董事會領導,他們擁有深厚的免疫學和免疫腫瘤學以及蛋白質生物製品設計和臨床開發方面的專業知識。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
總部位於馬薩諸塞州的波士頓,我們由一支經驗豐富的管理團隊和獨立的董事會領導,擁有在免疫學、免疫腫瘤學以及蛋白質生物製品的設計和臨床開發方面的深厚專業知識。
For more information please visit and follow us on X and LinkedIn.
Marie Campinell 高級總監,企業傳訊 Cue Biopharma, Inc.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投資者聯繫方式
Marie Campinell
高級董事,企業通信
cue biopharma,全球貨幣
mcampinell@cuebiopharma.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒體聯繫人
Jonathan Pappas
通信-半導體
jpappas@lifescicomms.com